e-Therapeutics PLC (LSE:ETX) - Overview

Stock Report

e-Therapeutics PLC ETX

Last Price
GBX8.38

Day Change
0.00|0.00%

As of 08/12/2016
13:10:09 GMT | GBX
Minimum 15 Minutes Delay.

Last Close8.38p
Day Range8.30 - 8.30
Mkt Cap22.49Mil
52-Wk Range8.30 - 27.50
Yield %0.00
ISINGB00B2823H99
Volume7,000
P/E-2.51
P/SInfinity
P/CF-2.50

Share Price

Total Returns 08/12/2016

 Chg (%)  
More ...
e-Therapeutics PLC-8.22 
FTSE 100 TR GBP1.73
 
Financials
201420152016
More ...
Income Statement
Turnover0.000.000.00
Operating Profit-6.72-10.18-11.56
Net Profit-5.04-7.78-8.82
Reported EPS-1.98-2.94-3.34
Balance Sheet
Current Assets45.0037.4228.78
Non Current Assets0.620.730.80
Total Assets45.6238.1629.59
Current Liabilities1.001.131.16
Total Liabilities1.001.131.16
Total Equity44.6237.0228.43
Cash Flow
Operating Cash Flow-6.55-10.94-10.93
Net Change in Cash2.67-5.084.52
Broker Forecasts
Year EndingPre-taxEPSEPSgP/EPEGDPSYld %
More ...
'Broker Forecasts' provides consensus figures based on several brokers' views
2017-12.63-3.70--2.27---
2018-8.87-2.70--3.10---

Regulatory News

Director Dealings
TradedActionNotifierPriceAmountValue
More ...
12/10/2016PurchaseProfessor Trevor Jones11.3341,2044,667.00
28/09/2016PurchaseSean Nicolson14.552,166315.00
21/09/2016Transfer inSean Nicolson0.002,1660.00
13/06/2016PurchaseProfessor Malcolm Young14.553,350,228487,458.00

Company Profile

e-Therapeutics PLC discovers and develops drug compounds for out-licensing, with a focus on age-related diseases including cancer and central nervous system disorders.
 

Sector

Biotechnology

Market Position

1306 of 1863 Companies

Index

FTSE AIM All Share

Outlook

(20/09/2016) no outlook statement

Next Event 31/01/2017

Next year end (to be reported)
Ratios
CompSecMkt
More ...
PER (E)-2.9413.3915.97
Div Yld (E)0.004.244.18
PEG (E)0.000.220.27
ROCE-40.75204.18-30.67
Op Mrgn0.00-17.37-33.06
EPS Grwth0.009.7722.66
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00

Broker Sentiment

Strong Buy0
Buy0
Hold0
Sell0
Strong Sell0
  • Strong Sell
  • Strong Buy
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
More ...
Disclaimer
Directors
More ...
ChairmanMr. Iain Ross
Company SecretarySean Nicolson
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2016 Morningstar. All rights reserved.